Broker Recommendations
Canaccord Genuity upgrades Hurricane Energy to 'buy'
Analysts at Canaccord Genuity raised Hurricane Energy to 'buy' from 'speculative buy' on Monday, highlighting some "fresh operational information" on its Lancaster early production system project in the group's interim results.
Berenberg upgrades Petra Diamonds after share price weakness
Berenberg upgraded its stance on Petra Diamonds stock to 'hold' from 'sell' on Monday, lifting the price target to 9p from 8p following weakness in the shares over the summer.
Cannacord hikes target on Intermediate Capital Group, stays at 'conviction buy'
Analysts at Cannacord Genuity reiterated their 'conviction buy' recommendation for shares of Intermediate Capital Group following the asset manager's latest half-year figures.
Berenberg lowers price target on Keywords Studios
Analysts at Berenberg lowered their price target on technical and creative services firm Keywords Studios from 1,620p to 1,400p on Friday on the back of the group's own reduced forecasts for margins and profits, but argued that the company's "multi-year equity story" was not broken but rather "on pause".
Canaccord upgrades Petropavlovsk to 'buy'
Analysts at Canaccord Genuity upped their stance on London-based gold mining company Petropavlovsk from 'speculative buy' to 'buy' on Thursday, stating that some increased clarity had given it the confidence to upgrade.
RBC Capital Markets downgrades Ferguson on short-term caution
RBC Capital Markets downgraded shares of plumbing merchant Ferguson to 'underperform' from 'sector perform' on Thursday, trimming the price target to 5,100p from 5,200p on short-term caution.
Thursday broker round-up
Ferguson: RBC Capital Markets downgrades to underperform with a target price of 5,100p.
Jefferies ups Centrica to 'buy', downgrades United Utilities and Severn Trent
Jefferies upped its stance on Centrica shares on Thursday as it highlighted an attractive risk/reward in a broader note on utilities, in which it referred to the stock as a "value wildcard".
Berenberg ups target on NMC Health as bear case goes into hibernation
Analysts at Berenberg raised their target price on healthcare provider NMC Health from £36 to £40 on Wednesday, stating that its bear case was "going into hibernation" following the group's recent first-half results.
Wednesday broker round-up
Weir Group: JP Morgan downgrades to neutral with a target price of 1,500p.
Liberum slashes Sirius Minerals price target after miner pulls bond sale
Broker Liberum slashed its price target on buy-rated Sirius Minerals to 9p from 40p on Wednesday a day after the company pulled a $500m bond sale that was crucial to unlocking a $2. 5bn credit facility from JPMorgan needed to finance its potash mine in Yorkshire.
JPMorgan downgrades Weir, cites challenges in oil & gas
JPMorgan Cazenove downgraded its rating on shares of Weir Group to ‘neutral’ from ‘overweight’ on Wednesday, cutting the price target to 1,500p from 1,650p as it said oil & gas challenges were set to persist as it reviewed its investment case after recent share price strength.
Berenberg restarts coverage on St James's Place at 'buy'
Analysts at Berenberg re-initiated coverage of wealth management firm St James's Place on Tuesday, hitting the group with a 'buy' rating and 1,194p target price.
Credit Suisse backs easyJet's Germany strategy
Credit Suisse has backed easyJet, arguing that the budget airline is successfully navigating a difficult market.
Jefferies start InterContinental at 'buy', Whitbread at 'hold'
Jefferies initiated coverage of InterContinental Hotels Group and Whitbread on Tuesday as it took a look at the European hotels sector.
Peel Hunt lowers target price on Synthomer ahead of OMNOVA acquisition
Analysts at Peel Hunt trimmed their target price for shares of British chemicals firm Synthomer from 450p to 435p on Monday, noting that opportunities stemming from its proposed acquisition of OMNOVA Solutions should offset weak European demand.
JP Morgan applauds AstraZeneca's growth outlook
JP Morgan has reiterated its ‘overweight’ rating on AstraZeneca, arguing that it has the strongest growth outlook of all the European drugs majors.